相关实验视频
Updated: Jan 16, 2026

07:30
Robot-Assisted Kidney Transplantation
Published on: July 19, 2021
4.2K
再组合的α-1微球蛋白可改善AKI幸存者的治疗结果
Matteo Marcello1,2,3, Ludwig Maximilian Schöne1, Hendrik Booke1
1Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Muenster, University of Muenster, Muenster, Germany.
概括
再组合的α-1微球蛋白 (A1M),称为RMC-035,显示了在手术后预防急性损伤 (AKI) 的潜力. 虽然最初的试验结果各不相同,但进一步的研究正在探索其长期的保护作用.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 手术 手术 手术 术 术
背景情况:
- 急性损伤 (AKI) 是大手术后的常见和严重并发症.
- 病理生理学涉及缺血-反,氧化应激和血液毒性.
- 再组合的α-1微球蛋白 (A1M) 正在作为保护剂进行研究.
研究的目的:
- 评估RMC-035 (A1M) 在预防外科手术期间的AKI的安全性和有效性.
- 评估RMC-035在高风险手术患者中的脏保护潜力.
- 探索长期脏结果和RMC-035.35的最佳剂量策略.
主要方法:
- 临床前研究使用了体外和动物模型来评估A1M的保护作用.
- 第1期临床试验评估了安全性,药理动力学和早期脏生物标志物.
- 第二阶段试验评估了心脏手术后的AKI率和重大脏不良事件.
主要成果:
- 临床前数据显示,A1M减轻了细胞损伤,并防止了缺血-再输液损伤.
- 第一阶段试验证实了RMC-035的安全性,并显示了早期的保护信号.
- 一项2期试验没有达到其主要AKI终点,但显示90天的脏不良事件减少,特别是持续的功能障碍.
结论:
- RMC-035显示出良好的安全性和长期保护的潜力.
- 需要进一步的研究,包括正在进行的2b期研究,以确认疗效和优化剂量.
- 在具有氧化应激和缺血-再输液损伤的手术环境中,RMC-035可能会带来好处.
更多相关视频
相关概念视频
Acute Kidney Injury I: Introduction
577
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
577
Acute Kidney Injury IV: Diagnostic Studies and Prevention
260
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
260
Acute Kidney Injury V: Interprofessional Care
297
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
297
Acute Kidney Injury II: Pathophysiology
899
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
899
Acute Kidney Injury VI: Nursing Management
392
Acute Kidney Injury (AKI) results in an inability to maintain fluid, electrolyte, and acid-base balance. Effective nursing management is critical in improving patient outcomes and includes comprehensive patient assessment and targeted interventions.Comprehensive Patient AssessmentA detailed history collection is essential, focusing on any recent infections, nephrotoxic medication use, or chronic conditions such as hypertension and diabetes that may contribute to AKI. During the physical...
392
Acute Kidney Injury III: Clinical Manifestations
825
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
825

